Loading organizations...
Key people at Thyreos.
Thyreos develops advanced herpesvirus vaccines and vaccine vectors for both animal and human health applications. The company leverages its proprietary R2 recombinant herpesvirus platform, engineered to elicit robust immune responses. This technology prevents the virus from entering the nervous system, thereby avoiding latency and disease expression.
Founded in January 2021, Thyreos emerged from the expertise of Dr. Gary Pickard of the University of Nebraska-Lincoln, Dr. Gregory Smith from Northwestern University, and Dr. Ekaterina Heldwein of Tufts University. Their insight focused on the R2 technology’s potential for safe, effective live-attenuated vaccines. Eric Zeece assumed the CEO role in November 2020, guiding the company's early development.
Thyreos targets partnerships with established animal and human health companies to commercialize its products. Its solutions benefit people, companion animals, and livestock, addressing critical health challenges. The company’s vision is to create products that reduce suffering and improve lives through its innovative vaccine strategies.
Key people at Thyreos.
Thyreos is a early-stage vaccine company developing a patented recombinant herpesvirus (R2) platform to create safe, live-attenuated vaccines and vaccine vectors for both animal and human health applications, with programs focused on preventing herpesvirus infection without neural latency and on animal-health targets first while exploring human indications such as HSV prophylaxis and vector uses.[4][3]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Biotech Landscape
Quick Take & Future Outlook